OTLK · Outlook Therapeutics Inc
United States · RS rating 30 · As of 2026-11-03
| Price | 0.46 USD |
|---|---|
| 1-day change | -1.9% |
| RS rating (overall / 1M / 3M / 12M) | 30 / 19 / 7 / 15 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 25 / 16 / 24 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +86.8% |
| Sales growth Q/Q | -1215.9% |
| Distance from 52-week high | +81.4% |
| Market cap (USD) | $34.6M |